Uso de probióticos em doenças autoimunes gastrointestinais: Uma revisão sistemática / The use of probiotics in gastrointestinal autoimmune diseases: A systematic review

Authors

  • Jennifer Alexandra Castanho Vieira Fried
  • Luciana Oliveira de Fariña

DOI:

https://doi.org/10.34119/bjhrv3n6-193

Keywords:

Probióticos, inflamação, microbiota intestinal, imunomodulação.

Abstract

Os probióticos afetam beneficamente a microbiota intestinal, estimulando os mecanismos imunológicos e não imunológicos da mucosa intestinal, por meio de um antagonismo com os patógenos potenciais. Nas doenças autoimunes, o sistema imunológico ataca e prejudica o próprio organismo, sendo que muitas dessas doenças afetam o sistema gastrointestinal. O objetivo deste trabalho foi avaliar o uso de bactérias probióticas no tratamento de doenças autoimunes, por meio de uma revisão sistemática em estudos in vivo conduzidos em pacientes portadores de doenças autoimunes do sistema gastrointestinal (gastrite autoimune; doenças inflamatórias intestinais: doença de Crohn e colite ulcerativa; doença celíaca e enteropatia autoimune). Dessa forma, foi realizada uma revisão sistemática nas seguintes bases de dados: Pubmed, Cochrane Library, Scopus e Web of Science, utilizando estratégias avançadas de busca. O gerenciamento dos dados foi feito com a utilização dos programas Microsoft Office Excel e EndNote. Foram recuperados 2868 artigos, sendo que, após a triagem de artigos duplicados e a avaliação dos resumos quanto aos critérios de elegibilidade, foram selecionados 47 artigos para o desenvolvimento da revisão sistemática. Dentre os artigos selecionados, a grande maioria foi referente à colite ulcerativa, apresentando 81,08 % com desfecho benéfico quanto ao uso de probióticos; já referente à doença de Crohn, apenas 55,56 % apresentaram desfecho positivo. No que tange à doença celíaca, 85,71 % demonstraram efeito benéfico referente ao uso de probióticos. Não foram selecionados artigos referentes à gastrite autoimune e nem à enteropatia autoimune. Após avaliação dos artigos, sugere-se que a intervenção de probióticos apresente benefícios no tratamento da doença celíaca juntamente à dieta livre de glúten. Já referente às DIIs, sugere-se que a ingestão de probióticos também apresente benefícios em pacientes com colite ulcerativa, no entanto, não é possível concluir o efeito benéfico no uso de probióticos especificamente na doença de Crohn.

References

ALTUN, H. K.; YILDIZ, E. A.; AKIN, M. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study. Turkish Journal of Gastroenterology, 30, n. 4, p. 313-320, 2019.

BALLINI, A.; SANTACROCE, L.; CANTORE, S.; BOTTALICO, L. et al. Probiotics Efficacy on Oxidative Stress Values in Inflammatory Bowel Disease: A Randomized Double-Blinded Placebo-Controlled Pilot Study. Endocrine, Metabolic and Immune Disorders - Drug Targets, v. 19, n. 3, p. 373-381, 2019.

BJARNASON, I.; SISSION, G.; HAYEE, B. H. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology, v. 27, n. 3, p. 465-473, 2019.

BOUSVAROS, A.; GUANDALINI, S.; BALDASSANO, R. N.; BOTELHO, C. et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflammatory Bowel Diseases, v.11, n. 9, p. 833-839, 2005.

BRASIL, Agência Nacional de Vigilância Sanitária. Resolução da diretoria colegiada - RDC nº 241, de 26 de julho de 2018. Diário Oficial da União, Brasília, DF, 27 de julho de 2018, edição 144, seção 1, 2018.

CHERMESH, I.; TAMIR, A.; RESHEF, R.; CHOWERS, Y. et al. Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Digestive Diseases and Sciences, v. 52, n. 2, p. 385-389, 2007.

COLLADO MC, DONAT E, RIBES-KONINCKX C, CALABUIG M, SANZ Y. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. Journal of Clinical Pathology., v. 62, p. 264–269, 2009.

CUMMINGS JH, MACFARLANE GT, MACFARLANE S. Intestinal bacteria and ulcerative colitis. Current Issues in Intestinal Microbiology. v. 4, p.9–20, 2003.

DARGAHI, N. et al. Immunomodulatory effects of probiotics: Can they be used to treat allergies and autoimmune diseases? Maturitas, v. 119, p. 25–38, 2019.

DE PALMA G, CINOVA J, STEPANKOVA R, TUCKOVA L, SANZ Y. Pivotal Advance: Bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. Journal of Leukocyte Biology, v. 87, p. 765 - 778, 2010.

DI CAGNO R, DE ANGELIS M, DE PASQUALE I, et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiology. v. 11, p. 219, 2011.

D'INCA, R.; BAROLLO, M.; SCARPA, M.; GRILLO, A. R. et al. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Digestive Diseases and Sciences, v. 56, n. 4, p. 1178-1187, Apr 2011.

EISENHARDT SU, THIELE JR, BANNASCH H, STARK GB, PETER K. C-reactive protein: how conformational changes influence inflammatory properties. Cell Cycle v. 8, n. 23, p. 3885 – 3892, 2009.

FAN H, DU J, LIU X, et al. Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease. Turkist Journal of Gastroenterology, v. 30, n. 8, p. 680-685, 2019.

FEDERICO, A.; TUCCILLO, C.; GROSSI, E.; ABBIATI, R. et al. The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: A pilot study. European Review for Medical and Pharmacological Sciences, v. 13, n. 4, p. 285-293, 2009.

FERREIRA, A. A. Papel Do Sistema Imune E Atuação Dos Probióticos Na Doença. Arquivos de ciências da saúde de UNIPAR, v. 14, n. 2, p. 171–177, 2010.

FOOD AND AGRICULTURE ORGANIZATION (FAO). WORLD HEALTH ORGANIZATION (WHO. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO Food nd Nutrition Paper, v. 85, p. 1–4, 2001.

FRANCAVILLA, R.; PICCOLO, M.; FRANCAVILLA, A.; POLIMENO, L. et al. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients with Persistent IBS-type Symptoms: a Randomized, Double-Blind, Placebo-controlled, Multicenter Trial. Journal of clinical gastroenterology, v. 53, n. 3, p. E117?e125, 2019.

FUJIMORI, S.; GUDIS, K.; MITSUI, K.; SEO, T. et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition, v. 25, n. 5, p. 520-525, 2009.

FURRIE, E.; MACFARLANE, S.; KENNEDY, A.; CUMMINGS, J. H. et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut, v. 54, n. 2, p. 242-249, Feb 2005.

GROEGER, D.; O'MAHONY, L.; MURPHY, E. F.; BOURKE, J. F. et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, v. 4, n. 4, p. 325-339, Jul-Aug 2013.

HARNETT, J.; MYERS, S. P.; ROLFE, M. Probiotics and the Microbiome in Celiac Disease: A Randomised Controlled Trial. Evidence-Based Complementary and Alternative Medicine, 2016.

HEGAZY, S. K.; EL-BEDEWY, M. M. Effect of probiotics on pro-inflammatory cytokines and NF-?b activation in ulcerative colitis. World Journal of Gastroenterology, v. 16, n. 33, p. 4145-4151, 2010.

HUANG, M. ;CHEN, Z. ;LANG, C. ;CHEN, J. ;YANG, B. ;XUE, L. ;ZHANG, Y. Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors

Pakistan Journal of Pharmaceutical Sciences, v. 31, p. 2891-2895, 2018.

ISHIKAWA, H.; AKEDO, I.; UMESAKI, Y.; TANAKA, R. et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. Journal of the American College of Nutrition, v. 22, n. 1, p. 56?63, 2003.

ISHIKAWA, H.; MATSUMOTO, S.; OHASHI, Y.; IMAOKA, A. et al. Beneficial Effects of Probiotic Bifidobacterium and Galacto-Oligosaccharide in Patients with Ulcerative Colitis: A Randomized Controlled Study. Digestion, v. 84, n. 2, p. 128-133, 2011.

KATO, K.; MIZUNO, S.; UMESAKI, Y.; ISHII, Y. et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology & Therapeutics, v. 20, n. 10, p. 1133-1141, Nov 15 2004.

KLEMENAK, M.; DOLINSEK, J.; LANGERHOLC, T.; DI, G. D. et al. Administration of Bifidobacterium breve Decreases the Production of TNF-alpha in Children with Celiac Disease. Digestive diseases and sciences, v. 60, n. 11, p. 3386?3392, 2015.

KRAG, A.; MUNKHOLM, P.; ISRAELSEN, H.; VON RYBERG, B. et al. Profermin is Efficacious in Patients with Active Ulcerative Colitis-A Randomized Controlled Trial. Inflammatory Bowel Diseases, v. 19, n. 12, p. 2584-2592, Nov 2013.

KRUIS, W.; FRIC, P.; POKROTNIEKS, J.; LUKAS, M. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, v. 53, n. 11, p. 1617-1623, Nov 2004.

KULNIGG-DABSCH, S. Autoimmungastritis. Wiener Medizinische Wochenschrift, v. 166, n. 13–14, p. 424–430, 2016.

A LUNDIN, K.E.; SCOTT, H.; FAUSA, O.; THORSBY, E.; SOLID, L.M. T cells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Human Immunology. v. 41, p. 285 – 291, 1994.

LANGAN RC, GOTSCH PB, KRAFCZYK MA, SKILLINGE DD. Ulcerative colitis: diagnosis and treatment. American Family Physician, v. 76, p. 323-30, 2007.

MANUSCRIPT, A. Autoimmune Entheropathy. v. 14, n. 5, p. 380–385, 2014.

MAROTTA, F.; NAITO, Y.; TAJIRI, H.; LIGHTHOUSE, J. et al. Disrupted mucosal barrier in quiescent ulcerative colitis: Effect of metronidazole and of a symbiotic preparation in a pilot cross-over study. Chinese Journal of Digestive Diseases, v. 4, n. 4, p. 180-185, 2003.

MARTEAU, P.; LEMANN, M.; SEKSIK, P.; LAHARIE, D. et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut, v. 55, n. 6, p. 842-847, Jun 2006.

MATTHES, H.; KRUMMENERL, T.; GIENSCH, M.; WOLFF, C. et al. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complementary and Alternative Medicine, v. 10, 2010.

MEDINA M, DE PALMA G, RIBES-KONINCKX C, CALABUIG M, SANZ Y. Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. Journal of Inflammation (Lond), v. 5, p.19, 2008.

MIZOGUCHI A, MIZOGUCHI E, BHAN AK: Immune networks in animal models of inflammatory bowel disease. Inflammatory Bowel Disease; v. 9, p.246–259, 2003.

MIELE, E.; PASCARELLA, F.; GIANNETTI, E.; QUAGLIETTA, L. et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology, v. 104, n. 2, p. 437-443, 2009.

MITCHELL, R. N. et al. Robbins e Cotran - Fundamentos de patologia. 9ªed. Rio de Janeiro: 2017.

MOHER, D. et al. Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiologia e Serviços de Saúde, v. 24, n. 2, p. 335–342, 2015.

NACHMAN F, MAURIN˜O E, VA´ZQUEZ H, et al. Quality of life in celiac disease patients. Prospective analysis on the importance of clinical severity at diagnosis and the impact of treatment. Digestive and Liver Disease. n. 41, p. 15–25, 2009.

NG, S.; PLAMONDON, S.; KAMM, M.; HART, A. et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflammatory bowel diseases, v.16, n. 8, p. 1286-1298, 2010.

OLIVA, S.; DI NARDO, G.; FERRARI, F.; MALLARDO, S. et al. Randomised clinical trial: The effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Alimentary Pharmacology and Therapeutics, 35, n. 3, p. 327-334, 2012.

OLIVARES, M.; CASTILLEJO, G.; VAREA, V.; SANZ, Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. British journal of nutrition, v.112, n. 1, p. 30?40, 2014.

PALUMBO, V.; ROMEO, M.; MARINO, G. A.; CARINI, F. et al. The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study. Biomedical papers of the medical faculty of the university palacky, olomouc, czechoslovakia, v.160, n. 3, p. 372?377, 2016.

PETERSEN, A.; MIRSEPASI, H.; HALKJAER, S.; MORTENSEN, E. et al. Ciprofloxacin and probiotic Escherichia coli nissle as add-on treatment in active ulcerative colitis; a double-blinded randomized placebo controlled clinical trial. Gastroenterology. v.146, n. 5 suppl. 1, p. S?591, 2014.

PORBÉN, S. S. Influence of a combination of lactobacilli and bifidobacteria upon disease activity, stool pattern and nutritional status of ulcerative colitis patients. Nutricion Hospitalaria, v. 25, n. 6, p. 971-983, 2010.

PRANTERA, C.; SCRIBANO, M. L.; FALASCO, G.; ANDREOLI, A. et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut, v. 51, n. 3, p. 405-409, 2002.

QUAGLIARIELLO, A.; ALOISIO, I.; BOZZI, C. N.; LUISELLI, D. et al. Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: a Pilot Study. Nutrients, v.8, n. 10, 2016.

REMBACKEN, B.; SNELLING, A.; HAWKEY, P.; CHALMERS, D. et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (london, england), v.354, n. 9179, p. 635?639, 1999.

RHODES J, THOMAS G, EVANS BK. Inflammatory Bowel Disease Management. Drugs v. 53, p.189-94, 1997.

RUIZ, K. Capítulo 15 - Probióticos e Prebióticos. Nutracêuticos na prática: Terapias baseadas em evidências. 2a Edição ed. São Paulo: 2017.

SCHULTZ, M.; TIMMER, A.; HERFARTH, H. H.; SARTOR, R. B. et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterology, v. 4, 2004.

SHADNOUSH, M.; HOSSEINI, R. S.; KHALILNEZHAD, A.; NAVAI, L. et al. Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-blind, Placebo-controlled Clinical Trial. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v. 65, n. 4, p. 215-221, 2015.

SHADNOUSH, M.; HOSSEINI, R. S.; MEHRABI, Y.; DELPISHEH, A. et al. Probiotic yogurt affects pro- and anti-inflammatory factors in patients with inflammatory bowel disease. Iranian Journal of Pharmaceutical Research, v.12, n. 4, p. 929-936, 2013.

SCHUPPAN D, DENNIS MD, KELLY CP. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management. Nutricion on Clinical Care. v. 8, p. 54–69, 2005.

SMECUOL, E.; HWANG, H. J.; SUGAI, E.; CORSO, L. et al. Exploratory, Randomized, Double-blind, Placebo-controlled Study on the Effects of Bifidobacterium infantis Natren Life Start Strain Super Strain in Active Celiac Disease. Journal of Clinical Gastroenterology, v. 47, n. 2, p. 139-147, Feb 2013.

SMECUOL, E.; TEMPRANO, P.; COSTA, A.; SUGAI, E. et al. Effect of Bifidobacterium infantis nsl super strain in highly symptomatic celiac disease patients on long-term gluten-free diet. a pilot study. Gastroenterology, v.156, n. 6, p. S?119?, 2019.

SOOD, A.; MIDHA, V.; MAKHARIA, G.; AHUJA, V. et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clinical gastroenterology and hepatology, v.7, n. 11, p. 1202?1209, 1209.e1201, 2009.

STEED, H.; MACFARLANE, G. T.; BLACKETT, K. L.; BAHRAMI, B. et al. Clinical trial: The microbiological and immunological effects of synbiotic consumption - A randomized double-blind placebo-controlled study in active Crohn's disease. Alimentary Pharmacology and Therapeutics, v. 32, n. 7, p. 872-883, 2010.

TAMAKI, H.; NAKASE, H.; INOUE, S.; KAWANAMI, C. et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy, v. 28, n. 1, p. 67-74, Jan 2016.

TURSI, A.; BRANDIMARTE, G.; GIORGETTI, G. M.; FORTI, G. et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Medicinal Science Monitor, v. 10, n. 11, p. Pi126-131, Nov 2004.

TURSI, A.; BRANDIMARTE, G.; PAPA, A.; GIGLIO, A. et al. Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Gastroenterology, v.105, n. 10, p. 2218-2227, Oct 2010.

VAN, G. A.; DEWIT, O.; LOUIS, E.; DE, H. G. et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflammatory bowel diseases, v.13, n. 2, p. 135?142, 2007.

YOSHIMATSU, Y.; YAMADA, A.; FURUKAWA, R.; SONO, K. et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology, p. 21, n. 19, p. 5985-5994, 2015.

Published

2020-12-06

How to Cite

FRIED, J. A. C. V.; FARIÑA, L. O. de. Uso de probióticos em doenças autoimunes gastrointestinais: Uma revisão sistemática / The use of probiotics in gastrointestinal autoimmune diseases: A systematic review. Brazilian Journal of Health Review, [S. l.], v. 3, n. 6, p. 17872–17893, 2020. DOI: 10.34119/bjhrv3n6-193. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/21087. Acesso em: 28 mar. 2024.

Issue

Section

Original Papers